Loading clinical trials...
Loading clinical trials...
Evaluation of the Impact of a Pharmacovigilance Program Led by Advanced Practice Nursing on Patients and Professionals at Hospital: Intervention Study
HYPOTHESIS An advanced practice nursing intervention in the area of pharmacovigilance performed on patients and professionals improves the identification and reporting of suspected adverse drug reactions (ADR) and improves the overall experience of hospitalized patients.
PRIMARY OBJETIVES 1\. To assess whether an advanced nursing intervention improves the identification and reporting of suspected ADR. SECONDARY OBJECTIVES 1. To determine if an advanced nursing intervention improves the experience related to the use of medications measured through the QExPac-21 patient experience questionnaire. 2. Identify which factors associated with medications increase the risk of ADRs and the characteristics of the patients. 3. Know the incidence and describe ADRs: severity, preventability, and causality using validated scales. 4. Describe the degree of nursing intervention according to the North American Nursing Diagnosis Association (NANDA) Taxonomy, and the classification of nursing interventions (NIC) Related to drug use. 5. Quantify the number of interconsultation generated by patients and professionals related to the use of drugs. 6. Determine the degree of adherence and compliance with the regimens prescribed to the patients. STUDY DESIGN Prospective, randomized and controlled study of an intervention that compares a group of patients according to the usual practice of the nursing care process, against another on which a more intensive nursing intervention is carried out for the identification and notification of ADRs. It is carried out on a representative sample of patients admitted to a tertiary level hospital with 860 beds of the Madrid Health Service during the year 2022.
Age
All ages
Sex
ALL
Healthy Volunteers
Yes
Hospital San Carlos
Madrid, Spain
Start Date
May 1, 2022
Primary Completion Date
November 1, 2022
Completion Date
December 30, 2022
Last Updated
October 18, 2024
395
ACTUAL participants
Pharmacovigilance Program
OTHER
Lead Sponsor
Natalia Rodriguez Galan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05538065